FM60

FM60 is a potent and selective small molecule inhibitor of histone deacetylase 10 (HDAC10), exhibiting an IC50 of 0.9 nM in cellular assays. Developed through a collaboration between Georgetown University and Martin Luther University Halle-Wittenberg, FM60 is designed to enhance innate antitumor immunity by modulating the tumor microenvironment. Specifically, it promotes the polarization of macrophages from a pro-tumoral M2 phenotype to an anti-tumoral M1 phenotype, characterized by increased expression of proinflammatory markers such as iNOS and TNF-alpha and decreased expression of anti-inflammatory markers like Arginase1 and Fizz1. FM60 also regulates polyamine biosynthesis, which is critical for tumorigenesis. In preclinical studies using syngeneic murine melanoma models, intraperitoneal administration of FM60 at 50 mg/kg significantly reduced tumor growth and enhanced phagocytic activity, supporting its potential as an immunotherapeutic anticancer agent.